Response monitoring of infant acute myeloid leukemia treatment by quantification of the tumor specific MLL–FNBP1 fusion gene

[1]  W. Choi,et al.  The MLL recombinome of acute leukemias in 2013 , 2013, Leukemia.

[2]  D. Johnston,et al.  Diagnosis and management of acute myeloid leukemia in children and adolescents: recommendations from an international expert panel. , 2012, Blood.

[3]  T. Dingermann,et al.  Do Non-Genomically Encoded Fusion Transcripts Cause Recurrent Chromosomal Translocations? , 2012, Cancers.

[4]  D. Reinhardt,et al.  Favorable outcome in infants with AML after intensive first- and second-line treatment: an AML-BFM study group report , 2012, Leukemia.

[5]  R. Pieters,et al.  The heterogeneity of pediatric MLL-rearranged acute myeloid leukemia , 2011, Leukemia.

[6]  O. Haas,et al.  Prognostic impact of specific chromosomal aberrations in a large group of pediatric patients with acute myeloid leukemia treated uniformly according to trial AML-BFM 98. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  M. D. Boer,et al.  Bimodal distribution of genomic MLL breakpoints in infant acute lymphoblastic leukemia treatment , 2010, Leukemia.

[8]  S. Raimondi,et al.  Novel prognostic subgroups in childhood 11q23/MLL-rearranged acute myeloid leukemia: results of an international retrospective study. , 2009, Blood.

[9]  Scott A. Armstrong,et al.  MLL translocations, histone modifications and leukaemia stem-cell development , 2007, Nature Reviews Cancer.

[10]  A. Borkhardt,et al.  The formin‐binding protein 17, FBP17, binds via a TNKS binding motif to tankyrase, a protein involved in telomere maintenance , 2003, FEBS letters.

[11]  D. Cilloni,et al.  Assessment of minimal residual disease (MRD) in CBFbeta/MYH11-positive acute myeloid leukemias by qualitative and quantitative RT-PCR amplification of fusion transcripts , 2002, Leukemia.

[12]  S. Bojesen,et al.  The human formin-binding protein 17 (FBP17) interacts with sorting nexin, SNX2, and is an MLL-fusion partner in acute myelogeneous leukemia , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[13]  R. Berger,et al.  Minimal residual disease (MRD) in remission t(8;21) AML and in vivo differentiation detected by FISH and CD34+ cell sorting , 2001, Leukemia.

[14]  M. Caligiuri,et al.  Persistence of the AML1/ETO fusion transcript in patients treated with allogeneic bone marrow transplantation for t(8;21) leukemia. , 1996, Blood.

[15]  A. Berrebi,et al.  Review of clinical and haematological response to low‐dose cytosine arabinoside in acute myeloid leukaemia , 1987, European journal of haematology.